Xavier Rovira Algans

Dr. Xavier Rovira Algans

CSIC - Instituto de Quimica Avanzada de Cataluna (IQAC), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in Nature Chemical Biology
Verified
Journal Article
Closed access
LXLi Xue
Li Xue
XAXavier Rovira Algans
Xavier Rovira Algans
PSPauline Scholler
Pauline Scholler
HZHan Zhao
Han Zhao
JLJianfeng Liu
Jianfeng Liu
Philippe RondardPhilippe Rondard
Philippe Rondard

31 August 2014 in Nature Chemical Biology
Verified
Journal Article
Closed access
SPSilvia Pittolo
Silvia Pittolo
XGXavier Gomez-Santacana
Xavier Gomez-Santacana
KEKay Eckelt
Kay Eckelt
XAXavier Rovira Algans
Xavier Rovira Algans
JDJames Dalton
James Dalton
PGPau Gorostiza
Pau Gorostiza

29 June 2017 in eLife
Verified
Journal Article
Open access
DDDavid Moreno Delgado
David Moreno Delgado
TMThor Christian Møller
Thor Christian Møller
JSJeanne Ster
Jeanne Ster
Jesús GiraldoJesús Giraldo
Jesús Giraldo
DMDamien Maurel
Damien Maurel
JPJean-Philippe Pin
Jean-Philippe Pin
Metabotropic glutamate receptors (mGluRs) are mandatory dimers playing important roles in regulating CNS function. Although assumed to form exclusive homodimers, 16 possible heterodimeric mGluRs have been proposed but their existence in native cells remains elusive. Here, we set up two assays to specifically identify the pharmacological properties of rat mGlu heterodimers composed of mGlu2 and 4 subunits. We used either a heterodimer-specific conformational LRET-based biosensor or a system that guarantees the cell surface targeting of the heterodimer only. We identified mGlu2-4 specific pharmacological fingerprints that were also observed in a neuronal cell line and in lateral perforant path terminals naturally expressing mGlu2 and mGlu4. These results bring strong evidence for the existence of mGlu2-4 heterodimers in native cells. In addition to reporting a general approach to characterize heterodimeric mGluRs, our study opens new avenues to understanding the pathophysiological roles of mGlu heterodimers.

1 August 2016 in Cell Chemical Biology
Verified
Journal Article
Closed access
XAXavier Rovira Algans
Xavier Rovira Algans
ATAna Trapero
Ana Trapero
SPSilvia Pittolo
Silvia Pittolo
CZCharleine Zussy
Charleine Zussy
Adèle FaucherreAdèle Faucherre
Adèle Faucherre
ALAmadeu Llebaría
Amadeu Llebaría

1 January 2010 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
XAXavier Rovira Algans
Xavier Rovira Algans
JPJean-Philippe Pin
Jean-Philippe Pin
Jesús GiraldoJesús Giraldo
Jesús Giraldo

6 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
PSPauline Scholler
Pauline Scholler
DNDamien Nevoltris
Damien Nevoltris
DBDimitri De Bundel
Dimitri De Bundel
SBSimon Bossi
Simon Bossi
DMDavid Moreno-Delgado
David Moreno-Delgado
JPJean-Philippe Pin
Jean-Philippe Pin
Antibodies have enormous therapeutic and biotechnology potential. G protein-coupled receptors (GPCRs), the main targets in drug development, are of major interest in antibody development programs. Metabotropic glutamate receptors are dimeric GPCRs that can control synaptic activity in a multitude of ways. Here we identify llama nanobodies that specifically recognize mGlu2 receptors, among the eight subtypes of mGluR subunits. Among these nanobodies, DN10 and 13 are positive allosteric modulators (PAM) on homodimeric mGlu2, while DN10 displays also a significant partial agonist activity. DN10 and DN13 have no effect on mGlu2-3 and mGlu2-4 heterodimers. These PAMs enhance the inhibitory action of the orthosteric mGlu2/mGlu3 agonist, DCG-IV, at mossy fiber terminals in the CA3 region of hippocampal slices. DN13 also impairs contextual fear memory when injected in the CA3 region of hippocampal region. These data highlight the potential of developing antibodies with allosteric actions on GPCRs to better define their roles in vivo.